Key result
During pegylated interferon-based treatment for chronic hepatitis C, 22.4% of patients developed depressive disorder, with pretreatment subthreshold mood symptoms significantly predicting its onset.
Why the study?
What is the incidence and what are the predictors of depression during pegylated interferon-based treatment in patients with chronic hepatitis C?
Population
67 treatment-naïve patients with chronic hepatitis C without depression at baseline
Design
Cohort
Follow-up
up to 48 weeks
Authors
Loading...
May warrant pretreatment mood screening before pegylated interferon; leaves open whether intervention reduces depression incidence.
Cohort (n=67)
No
What is the incidence and what are the predictors of depression during pegylated interferon-based treatment in patients with chronic hepatitis C?
A significant proportion of patients with chronic hepatitis C develop depression during pegylated interferon-based treatment, highlighting the need for early psychiatric assessment.
Choi et al. (2017) conducted a cohort in Chronic hepatitis C (n=67). Pegylated interferon-alpha-2a plus ribavirin vs. Baseline (pre-treatment) was evaluated on Development of depressive disorder (major depressive disorder or subsyndromal depression). During pegylated interferon-based treatment for chronic hepatitis C, 22.4% of patients developed depressive disorder, with pretreatment subthreshold mood symptoms significantly predicting its onset.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: